Please use this identifier to cite or link to this item:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/27233Full metadata record
| ???org.dspace.app.webui.jsptag.ItemTag.dcfield??? | Value | Language |
|---|---|---|
| dc.contributor.advisor | 葉秀慧 | |
| dc.contributor.author | Ching-Ju Chang | en |
| dc.contributor.author | 張靜如 | zh_TW |
| dc.date.accessioned | 2021-06-12T17:58:39Z | - |
| dc.date.available | 2018-12-31 | |
| dc.date.copyright | 2008-02-20 | |
| dc.date.issued | 2008 | |
| dc.date.submitted | 2008-01-29 | |
| dc.identifier.citation | [1] P. Tiollais, C. Pourcel, and A. Dejean, 'The hepatitis B virus,' Nature, vol. 317, pp. 489-95, Oct 10-16 1985.
[2] W. Szmuness, C. E. Stevens, E. J. Harley, E. A. Zang, P. E. Taylor, and H. J. Alter, 'The immune response of healthy adults to a reduced dose of hepatitis B vaccine,' J Med Virol, vol. 8, pp. 123-9, 1981. [3] C. Seeger, D. Ganem, and H. E. Varmus, 'Biochemical and genetic evidence for the hepatitis B virus replication strategy,' Science, vol. 232, pp. 477-84, Apr 25 1986. [4] T. Maruyama, S. Iino, K. Koike, K. Yasuda, and D. R. Milich, 'Serology of acute exacerbation in chronic hepatitis B virus infection,' Gastroenterology, vol. 105, pp. 1141-51, Oct 1993. [5] O. Jean-Jean, M. Levrero, H. Will, M. Perricaudet, and J. M. Rossignol, 'Expression mechanism of the hepatitis B virus (HBV) C gene and biosynthesis of HBe antigen,' Virology, vol. 170, pp. 99-106, May 1989. [6] S. M. Oberhaus and J. E. Newbold, 'Detection of an RNase H activity associated with hepadnaviruses,' J Virol, vol. 69, pp. 5697-704, Sep 1995. [7] H. Nakatake, O. Chisaka, S. Yamamoto, K. Matsubara, and R. Koshy, 'Effect of X protein on transactivation of hepatitis B virus promoters and on viral replication,' Virology, vol. 195, pp. 305-14, Aug 1993. [8] D. S. Chen, 'Public health measures to control hepatitis B virus infection in the developing countries of the Asia-Pacific region,' J Gastroenterol Hepatol, vol. 15 Suppl, pp. E7-10, May 2000. [9] K. Huang and S. Lin, 'Nationwide vaccination: a success story in Taiwan,' Vaccine, vol. 18 Suppl 1, pp. S35-8, Feb 18 2000. [10] A. J. Zuckerman, 'More than third of world's population has been infected with hepatitis B virus,' BMJ, vol. 318, p. 1213, May 1 1999. [11] J. E. Maynard, 'Hepatitis B: global importance and need for control,' Vaccine, vol. 8 Suppl, pp. S18-20; discussion S21-3, Mar 1990. [12] H. S. Margolis, M. J. Alter, and S. C. Hadler, 'Hepatitis B: evolving epidemiology and implications for control,' Semin Liver Dis, vol. 11, pp. 84-92, May 1991. [13] M. Dehesa-Violante and R. Nunez-Nateras, 'Epidemiology of hepatitis virus B and C,' Arch Med Res, vol. 38, pp. 606-11, Aug 2007. [14] I. Merican, R. Guan, D. Amarapuka, M. J. Alexander, A. Chutaputti, R. N. Chien, S. S. Hasnian, N. Leung, L. Lesmana, P. H. Phiet, H. M. Sjalfoellah Noer, J. Sollano, H. S. Sun, and D. Z. Xu, 'Chronic hepatitis B virus infection in Asian countries,' J Gastroenterol Hepatol, vol. 15, pp. 1356-61, Dec 2000. [15] R. P. Beasley, L. Y. Hwang, C. C. Lin, and C. S. Chien, 'Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan,' Lancet, vol. 2, pp. 1129-33, Nov 21 1981. [16] M. W. Yu, S. H. Yeh, P. J. Chen, Y. F. Liaw, C. L. Lin, C. J. Liu, W. L. Shih, J. H. Kao, D. S. Chen, and C. J. Chen, 'Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men,' J Natl Cancer Inst, vol. 97, pp. 265-72, Feb 16 2005. [17] R. P. Beasley and L. Y. Hwang, 'Hepatocellular carcinoma and hepatitis B virus,' Semin Liver Dis, vol. 4, pp. 113-21, May 1984. [18] K. Matsubara and T. Tokino, 'Integration of hepatitis B virus DNA and its implications for hepatocarcinogenesis,' Mol Biol Med, vol. 7, pp. 243-60, Jun 1990. [19] B. L. Slagle, Y. Z. Zhou, and J. S. Butel, 'Hepatitis B virus integration event in human chromosome 17p near the p53 gene identifies the region of the chromosome commonly deleted in virus-positive hepatocellular carcinomas,' Cancer Res, vol. 51, pp. 49-54, Jan 1 1991. [20] T. Moroy, A. Marchio, J. Etiemble, C. Trepo, P. Tiollais, and M. A. Buendia, 'Rearrangement and enhanced expression of c-myc in hepatocellular carcinoma of hepatitis virus infected woodchucks,' Nature, vol. 324, pp. 276-9, Nov 20-26 1986. [21] F. V. Chisari, P. Filippi, J. Buras, A. McLachlan, H. Popper, C. A. Pinkert, R. D. Palmiter, and R. L. Brinster, 'Structural and pathological effects of synthesis of hepatitis B virus large envelope polypeptide in transgenic mice,' Proc Natl Acad Sci U S A, vol. 84, pp. 6909-13, Oct 1987. [22] F. V. Chisari, 'Hepatitis B virus gene expression in transgenic mice,' Mol Biol Med, vol. 6, pp. 143-9, Apr 1989. [23] W. H. Caselmann, 'Transactivation of cellular gene expression by hepatitis B viral proteins: a possible molecular mechanism of hepatocarcinogenesis,' J Hepatol, vol. 22, pp. 34-7, 1995. [24] M. W. Yu, Y. C. Yang, S. Y. Yang, S. W. Cheng, Y. F. Liaw, S. M. Lin, and C. J. Chen, 'Hormonal markers and hepatitis B virus-related hepatocellular carcinoma risk: a nested case-control study among men,' J Natl Cancer Inst, vol. 93, pp. 1644-51, Nov 7 2001. [25] M. W. Yu, S. W. Cheng, M. W. Lin, S. Y. Yang, Y. F. Liaw, H. C. Chang, T. J. Hsiao, S. M. Lin, S. D. Lee, P. J. Chen, C. J. Liu, and C. J. Chen, 'Androgen-receptor gene CAG repeats, plasma testosterone levels, and risk of hepatitis B-related hepatocellular carcinoma,' J Natl Cancer Inst, vol. 92, pp. 2023-8, Dec 20 2000. [26] S. E. Rundlett, X. P. Wu, and R. L. Miesfeld, 'Functional characterizations of the androgen receptor confirm that the molecular basis of androgen action is transcriptional regulation,' Mol Endocrinol, vol. 4, pp. 708-14, May 1990. [27] H. P. Gerber, K. Seipel, O. Georgiev, M. Hofferer, M. Hug, S. Rusconi, and W. Schaffner, 'Transcriptional activation modulated by homopolymeric glutamine and proline stretches,' Science, vol. 263, pp. 808-11, Feb 11 1994. [28] H. S. Chen, S. Kaneko, R. Girones, R. W. Anderson, W. E. Hornbuckle, B. C. Tennant, P. J. Cote, J. L. Gerin, R. H. Purcell, and R. H. Miller, 'The woodchuck hepatitis virus X gene is important for establishment of virus infection in woodchucks,' J Virol, vol. 67, pp. 1218-26, Mar 1993. [29] J. A. Kemppainen, M. V. Lane, M. Sar, and E. M. Wilson, 'Androgen receptor phosphorylation, turnover, nuclear transport, and transcriptional activation. Specificity for steroids and antihormones,' J Biol Chem, vol. 267, pp. 968-74, Jan 15 1992. [30] J. Benn, F. Su, M. Doria, and R. J. Schneider, 'Hepatitis B virus HBx protein induces transcription factor AP-1 by activation of extracellular signal-regulated and c-Jun N-terminal mitogen-activated protein kinases,' J Virol, vol. 70, pp. 4978-85, Aug 1996. [31] H. F. Maguire, J. P. Hoeffler, and A. Siddiqui, 'HBV X protein alters the DNA binding specificity of CREB and ATF-2 by protein-protein interactions,' Science, vol. 252, pp. 842-4, May 10 1991. [32] I. Haviv, M. Shamay, G. Doitsh, and Y. Shaul, 'Hepatitis B virus pX targets TFIIB in transcription coactivation,' Mol Cell Biol, vol. 18, pp. 1562-9, Mar 1998. [33] S. Takada, N. Kaneniwa, N. Tsuchida, and K. Koike, 'Hepatitis B virus X gene expression is activated by X protein but repressed by p53 tumor suppressor gene product in the transient expression system,' Virology, vol. 216, pp. 80-9, Feb 1 1996. [34] D. F. Spandau and C. H. Lee, 'trans-activation of viral enhancers by the hepatitis B virus X protein,' J Virol, vol. 62, pp. 427-34, Feb 1988. [35] M. Levrero, C. Balsano, G. Natoli, M. L. Avantaggiati, and E. Elfassi, 'Hepatitis B virus X protein transactivates the long terminal repeats of human immunodeficiency virus types 1 and 2,' J Virol, vol. 64, pp. 3082-6, Jun 1990. [36] C. Balsano, M. L. Avantaggiati, G. Natoli, E. De Marzio, H. Will, M. Perricaudet, and M. Levrero, 'Full-length and truncated versions of the hepatitis B virus (HBV) X protein (pX) transactivate the cmyc protooncogene at the transcriptional level,' Biochem Biophys Res Commun, vol. 176, pp. 985-92, May 15 1991. [37] J. S. Twu, M. Y. Lai, D. S. Chen, and W. S. Robinson, 'Activation of protooncogene c-jun by the X protein of hepatitis B virus,' Virology, vol. 192, pp. 346-50, Jan 1993. [38] J. Han, H. Y. Yoo, B. H. Choi, and H. M. Rho, 'Selective transcriptional regulations in the human liver cell by hepatitis B viral X protein,' Biochem Biophys Res Commun, vol. 272, pp. 525-30, Jun 7 2000. [39] B. Aufiero and R. J. Schneider, 'The hepatitis B virus X-gene product trans-activates both RNA polymerase II and III promoters,' EMBO J, vol. 9, pp. 497-504, Feb 1990. [40] Z. Zhang, N. Torii, A. Furusaka, N. Malayaman, Z. Hu, and T. J. Liang, 'Structural and functional characterization of interaction between hepatitis B virus X protein and the proteasome complex,' J Biol Chem, vol. 275, pp. 15157-65, May 19 2000. [41] Z. Hu, Z. Zhang, E. Doo, O. Coux, A. L. Goldberg, and T. J. Liang, 'Hepatitis B virus X protein is both a substrate and a potential inhibitor of the proteasome complex,' J Virol, vol. 73, pp. 7231-40, Sep 1999. [42] A. S. Kekule, U. Lauer, L. Weiss, B. Luber, and P. H. Hofschneider, 'Hepatitis B virus transactivator HBx uses a tumour promoter signalling pathway,' Nature, vol. 361, pp. 742-5, Feb 25 1993. [43] S. Murakami, J. Cheong, S. Ohno, K. Matsushima, and S. Kaneko, 'Transactivation of human hepatitis B virus X protein, HBx, operates through a mechanism distinct from protein kinase C and okadaic acid activation pathways,' Virology, vol. 199, pp. 243-6, Feb 15 1994. [44] J. Benn and R. J. Schneider, 'Hepatitis B virus HBx protein activates Ras-GTP complex formation and establishes a Ras, Raf, MAP kinase signaling cascade,' Proc Natl Acad Sci U S A, vol. 91, pp. 10350-4, Oct 25 1994. [45] N. P. Klein and R. J. Schneider, 'Activation of Src family kinases by hepatitis B virus HBx protein and coupled signaling to Ras,' Mol Cell Biol, vol. 17, pp. 6427-36, Nov 1997. [46] N. P. Klein, M. J. Bouchard, L. H. Wang, C. Kobarg, and R. J. Schneider, 'Src kinases involved in hepatitis B virus replication,' EMBO J, vol. 18, pp. 5019-27, Sep 15 1999. [47] M. J. Bouchard, L. H. Wang, and R. J. Schneider, 'Calcium signaling by HBx protein in hepatitis B virus DNA replication,' Science, vol. 294, pp. 2376-8, Dec 14 2001. [48] C. Tarn, S. Lee, Y. Hu, C. Ashendel, and O. M. Andrisani, 'Hepatitis B virus X protein differentially activates RAS-RAF-MAPK and JNK pathways in X-transforming versus non-transforming AML12 hepatocytes,' J Biol Chem, vol. 276, pp. 34671-80, Sep 14 2001. [49] Y. H. Lee and Y. Yun, 'HBx protein of hepatitis B virus activates Jak1-STAT signaling,' J Biol Chem, vol. 273, pp. 25510-5, Sep 25 1998. [50] E. Lara-Pezzi, S. Roche, O. M. Andrisani, F. Sanchez-Madrid, and M. Lopez-Cabrera, 'The hepatitis B virus HBx protein induces adherens junction disruption in a src-dependent manner,' Oncogene, vol. 20, pp. 3323-31, Jun 7 2001. [51] Y. Shirakata, M. Kawada, Y. Fujiki, H. Sano, M. Oda, K. Yaginuma, M. Kobayashi, and K. Koike, 'The X gene of hepatitis B virus induced growth stimulation and tumorigenic transformation of mouse NIH3T3 cells,' Jpn J Cancer Res, vol. 80, pp. 617-21, Jul 1989. [52] M. Seifer and W. H. Gerlich, 'Increased growth of permanent mouse fibroblasts in soft agar after transfection with hepatitis B virus DNA,' Arch Virol, vol. 126, pp. 119-28, 1992. [53] D. Y. Yu, H. B. Moon, J. K. Son, S. Jeong, S. L. Yu, H. Yoon, Y. M. Han, C. S. Lee, J. S. Park, C. H. Lee, B. H. Hyun, S. Murakami, and K. K. Lee, 'Incidence of hepatocellular carcinoma in transgenic mice expressing the hepatitis B virus X-protein,' J Hepatol, vol. 31, pp. 123-32, Jul 1999. [54] B. K. Wu, C. C. Li, H. J. Chen, J. L. Chang, K. S. Jeng, C. K. Chou, M. T. Hsu, and T. F. Tsai, 'Blocking of G1/S transition and cell death in the regenerating liver of Hepatitis B virus X protein transgenic mice,' Biochem Biophys Res Commun, vol. 340, pp. 916-28, Feb 17 2006. [55] O. Terradillos, O. Billet, C. A. Renard, R. Levy, T. Molina, P. Briand, and M. A. Buendia, 'The hepatitis B virus X gene potentiates c-myc-induced liver oncogenesis in transgenic mice,' Oncogene, vol. 14, pp. 395-404, Jan 30 1997. [56] C. R. Madden, M. J. Finegold, and B. L. Slagle, 'Hepatitis B virus X protein acts as a tumor promoter in development of diethylnitrosamine-induced preneoplastic lesions,' J Virol, vol. 75, pp. 3851-8, Apr 2001. [57] B. L. Slagle, T. H. Lee, D. Medina, M. J. Finegold, and J. S. Butel, 'Increased sensitivity to the hepatocarcinogen diethylnitrosamine in transgenic mice carrying the hepatitis B virus X gene,' Mol Carcinog, vol. 15, pp. 261-9, Apr 1996. [58] K. Reifenberg, J. Lohler, H. P. Pudollek, E. Schmitteckert, G. Spindler, J. Kock, and H. J. Schlicht, 'Long-term expression of the hepatitis B virus core-e- and X-proteins does not cause pathologic changes in transgenic mice,' J Hepatol, vol. 26, pp. 119-30, Jan 1997. [59] C. M. Kim, K. Koike, I. Saito, T. Miyamura, and G. Jay, 'HBx gene of hepatitis B virus induces liver cancer in transgenic mice,' Nature, vol. 351, pp. 317-20, May 23 1991. [60] K. Koike, K. Moriya, S. Iino, H. Yotsuyanagi, Y. Endo, T. Miyamura, and K. Kurokawa, 'High-level expression of hepatitis B virus HBx gene and hepatocarcinogenesis in transgenic mice,' Hepatology, vol. 19, pp. 810-9, Apr 1994. [61] N. Nagasue, A. Ito, H. Yukaya, and Y. Ogawa, 'Androgen receptors in hepatocellular carcinoma and surrounding parenchyma,' Gastroenterology, vol. 89, pp. 643-7, Sep 1985. [62] N. Nagasue and H. Kohno, 'Hepatocellular carcinoma and sex hormones,' HPB Surg, vol. 6, pp. 1-6, 1992. [63] N. Nagasue, A. Yamanoi, H. Kohno, T. Kimoto, Y. Chang, H. Taniura, M. Uchida, and T. Nakamura, 'Androgen receptor in cirrhotic liver, adenomatous hyperplastic nodule and hepatocellular carcinoma in the human,' Hepatogastroenterology, vol. 39, pp. 455-60, Oct 1992. [64] P. K. Eagon, M. S. Elm, M. J. Epley, H. Shinozuka, and K. N. Rao, 'Sex steroid metabolism and receptor status in hepatic hyperplasia and cancer in rats,' Gastroenterology, vol. 110, pp. 1199-207, Apr 1996. [65] S. D. Vesselinovitch, L. Itze, N. Mihailovich, and K. V. Rao, 'Modifying role of partial hepatectomy and gonadectomy in ethylnitrosourea-induced hepatocarcinogenesis,' Cancer Res, vol. 40, pp. 1538-42, May 1980. [66] Y. C. Toh, 'Effect of neonatal castration on liver tumor induction by N-2-fluorenylacetamide in suckling BALB/c mice,' Carcinogenesis, vol. 2, pp. 1219-21, 1981. [67] M. R. Moore, N. R. Drinkwater, E. C. Miller, J. A. Miller, and H. C. Pitot, 'Quantitative analysis of the time-dependent development of glucose-6-phosphatase-deficient foci in the livers of mice treated neonatally with diethylnitrosamine,' Cancer Res, vol. 41, pp. 1585-93, May 1981. [68] C. M. Lee, S. N. Lu, C. S. Changchien, C. T. Yeh, T. T. Hsu, J. H. Tang, J. H. Wang, D. Y. Lin, C. L. Chen, and W. J. Chen, 'Age, gender, and local geographic variations of viral etiology of hepatocellular carcinoma in a hyperendemic area for hepatitis B virus infection,' Cancer, vol. 86, pp. 1143-50, Oct 1 1999. [69] Y. Shiratori, S. Shiina, M. Imamura, N. Kato, F. Kanai, T. Okudaira, T. Teratani, G. Tohgo, N. Toda, M. Ohashi, and et al., 'Characteristic difference of hepatocellular carcinoma between hepatitis B- and C- viral infection in Japan,' Hepatology, vol. 22, pp. 1027-33, Oct 1995. [70] C. M. Chiu, S. H. Yeh, P. J. Chen, T. J. Kuo, C. J. Chang, W. J. Yang, and D. S. Chen, 'Hepatitis B virus X protein enhances androgen receptor-responsive gene expression depending on androgen level,' Proc Natl Acad Sci U S A, vol. 104, pp. 2571-8, Feb 20 2007. [71] H. Faus and B. Haendler, 'Post-translational modifications of steroid receptors,' Biomed Pharmacother, vol. 60, pp. 520-8, Nov 2006. [72] J. Prescott and G. A. Coetzee, 'Molecular chaperones throughout the life cycle of the androgen receptor,' Cancer Lett, vol. 231, pp. 12-9, Jan 8 2006. [73] S. Kousteni, T. Bellido, L. I. Plotkin, C. A. O'Brien, D. L. Bodenner, L. Han, K. Han, G. B. DiGregorio, J. A. Katzenellenbogen, B. S. Katzenellenbogen, P. K. Roberson, R. S. Weinstein, R. L. Jilka, and S. C. Manolagas, 'Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity,' Cell, vol. 104, pp. 719-30, Mar 9 2001. [74] E. Langley, Z. X. Zhou, and E. M. Wilson, 'Evidence for an anti-parallel orientation of the ligand-activated human androgen receptor dimer,' J Biol Chem, vol. 270, pp. 29983-90, Dec 15 1995. [75] E. Langley, J. A. Kemppainen, and E. M. Wilson, 'Intermolecular NH2-/carboxyl-terminal interactions in androgen receptor dimerization revealed by mutations that cause androgen insensitivity,' J Biol Chem, vol. 273, pp. 92-101, Jan 2 1998. [76] Z. X. Zhou, M. V. Lane, J. A. Kemppainen, F. S. French, and E. M. Wilson, 'Specificity of ligand-dependent androgen receptor stabilization: receptor domain interactions influence ligand dissociation and receptor stability,' Mol Endocrinol, vol. 9, pp. 208-18, Feb 1995. [77] B. He and E. M. Wilson, 'The NH(2)-terminal and carboxyl-terminal interaction in the human androgen receptor,' Mol Genet Metab, vol. 75, pp. 293-8, Apr 2002. [78] B. He, J. A. Kemppainen, and E. M. Wilson, 'FXXLF and WXXLF sequences mediate the NH2-terminal interaction with the ligand binding domain of the androgen receptor,' J Biol Chem, vol. 275, pp. 22986-94, Jul 28 2000. [79] B. He, N. T. Bowen, J. T. Minges, and E. M. Wilson, 'Androgen-induced NH2- and COOH-terminal Interaction Inhibits p160 coactivator recruitment by activation function 2,' J Biol Chem, vol. 276, pp. 42293-301, Nov 9 2001. [80] M. Saitoh, R. Takayanagi, K. Goto, A. Fukamizu, A. Tomura, T. Yanase, and H. Nawata, 'The presence of both the amino- and carboxyl-terminal domains in the AR is essential for the completion of a transcriptionally active form with coactivators and intranuclear compartmentalization common to the steroid hormone receptors: a three-dimensional imaging study,' Mol Endocrinol, vol. 16, pp. 694-706, Apr 2002. [81] J. Li, J. Fu, C. Toumazou, H. G. Yoon, and J. Wong, 'A role of the amino-terminal (N) and carboxyl-terminal (C) interaction in binding of androgen receptor to chromatin,' Mol Endocrinol, vol. 20, pp. 776-85, Apr 2006. [82] B. He, J. A. Kemppainen, J. J. Voegel, H. Gronemeyer, and E. M. Wilson, 'Activation function 2 in the human androgen receptor ligand binding domain mediates interdomain communication with the NH(2)-terminal domain,' J Biol Chem, vol. 274, pp. 37219-25, Dec 24 1999. [83] D. P. Edwards, 'The role of coactivators and corepressors in the biology and mechanism of action of steroid hormone receptors,' J Mammary Gland Biol Neoplasia, vol. 5, pp. 307-24, Jul 2000. [84] H. C. Shen, G. Buchanan, L. M. Butler, J. Prescott, M. Henderson, W. D. Tilley, and G. A. Coetzee, 'GRIP1 mediates the interaction between the amino- and carboxyl-termini of the androgen receptor,' Biol Chem, vol. 386, pp. 69-74, Jan 2005. [85] A. Bubulya, S. Y. Chen, C. J. Fisher, Z. Zheng, X. Q. Shen, and L. Shemshedini, 'c-Jun potentiates the functional interaction between the amino and carboxyl termini of the androgen receptor,' J Biol Chem, vol. 276, pp. 44704-11, Nov 30 2001. [86] S. Bai, B. He, and E. M. Wilson, 'Melanoma antigen gene protein MAGE-11 regulates androgen receptor function by modulating the interdomain interaction,' Mol Cell Biol, vol. 25, pp. 1238-57, Feb 2005. [87] L. Wang, C. L. Hsu, and C. Chang, 'Androgen receptor corepressors: an overview,' Prostate, vol. 63, pp. 117-30, May 1 2005. [88] C. J. Loy, K. S. Sim, and E. L. Yong, 'Filamin-A fragment localizes to the nucleus to regulate androgen receptor and coactivator functions,' Proc Natl Acad Sci U S A, vol. 100, pp. 4562-7, Apr 15 2003. [89] G. Liao, L. Y. Chen, A. Zhang, A. Godavarthy, F. Xia, J. C. Ghosh, H. Li, and J. D. Chen, 'Regulation of androgen receptor activity by the nuclear receptor corepressor SMRT,' J Biol Chem, vol. 278, pp. 5052-61, Feb 14 2003. [90] L. Wang, C. L. Hsu, J. Ni, P. H. Wang, S. Yeh, P. Keng, and C. Chang, 'Human checkpoint protein hRad9 functions as a negative coregulator to repress androgen receptor transactivation in prostate cancer cells,' Mol Cell Biol, vol. 24, pp. 2202-13, Mar 2004. [91] J. L. Shenk, C. J. Fisher, S. Y. Chen, X. F. Zhou, K. Tillman, and L. Shemshedini, 'p53 represses androgen-induced transactivation of prostate-specific antigen by disrupting hAR amino- to carboxyl-terminal interaction,' J Biol Chem, vol. 276, pp. 38472-9, Oct 19 2001. [92] L. Wang, H. K. Lin, Y. C. Hu, S. Xie, L. Yang, and C. Chang, 'Suppression of androgen receptor-mediated transactivation and cell growth by the glycogen synthase kinase 3 beta in prostate cells,' J Biol Chem, vol. 279, pp. 32444-52, Jul 30 2004. [93] K. Hughes, E. Nikolakaki, S. E. Plyte, N. F. Totty, and J. R. Woodgett, 'Modulation of the glycogen synthase kinase-3 family by tyrosine phosphorylation,' EMBO J, vol. 12, pp. 803-8, Feb 1993. [94] A. Cole, S. Frame, and P. Cohen, 'Further evidence that the tyrosine phosphorylation of glycogen synthase kinase-3 (GSK3) in mammalian cells is an autophosphorylation event,' Biochem J, vol. 377, pp. 249-55, Jan 1 2004. [95] D. A. Cross, D. R. Alessi, P. Cohen, M. Andjelkovich, and B. A. Hemmings, 'Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B,' Nature, vol. 378, pp. 785-9, Dec 21-28 1995. [96] R. S. Jope and G. V. Johnson, 'The glamour and gloom of glycogen synthase kinase-3,' Trends Biochem Sci, vol. 29, pp. 95-102, Feb 2004. [97] X. Fang, S. X. Yu, Y. Lu, R. C. Bast, Jr., J. R. Woodgett, and G. B. Mills, 'Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A,' Proc Natl Acad Sci U S A, vol. 97, pp. 11960-5, Oct 24 2000. [98] M. Li, X. Wang, M. K. Meintzer, T. Laessig, M. J. Birnbaum, and K. A. Heidenreich, 'Cyclic AMP promotes neuronal survival by phosphorylation of glycogen synthase kinase 3beta,' Mol Cell Biol, vol. 20, pp. 9356-63, Dec 2000. [99] X. Fang, S. Yu, J. L. Tanyi, Y. Lu, J. R. Woodgett, and G. B. Mills, 'Convergence of multiple signaling cascades at glycogen synthase kinase 3: Edg receptor-mediated phosphorylation and inactivation by lysophosphatidic acid through a protein kinase C-dependent intracellular pathway,' Mol Cell Biol, vol. 22, pp. 2099-110, Apr 2002. [100] C. Sutherland, I. A. Leighton, and P. Cohen, 'Inactivation of glycogen synthase kinase-3 beta by phosphorylation: new kinase connections in insulin and growth-factor signalling,' Biochem J, vol. 296 ( Pt 1), pp. 15-9, Nov 15 1993. [101] M. A. Buendia, 'Genetics of hepatocellular carcinoma,' Semin Cancer Biol, vol. 10, pp. 185-200, Jun 2000. [102] A. de La Coste, B. Romagnolo, P. Billuart, C. A. Renard, M. A. Buendia, O. Soubrane, M. Fabre, J. Chelly, C. Beldjord, A. Kahn, and C. Perret, 'Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas,' Proc Natl Acad Sci U S A, vol. 95, pp. 8847-51, Jul 21 1998. [103] T. Suzuki, H. Yano, Y. Nakashima, O. Nakashima, and M. Kojiro, 'Beta-catenin expression in hepatocellular carcinoma: a possible participation of beta-catenin in the dedifferentiation process,' J Gastroenterol Hepatol, vol. 17, pp. 994-1000, Sep 2002. [104] C. M. Wong, S. T. Fan, and I. O. Ng, 'beta-Catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance,' Cancer, vol. 92, pp. 136-45, Jul 1 2001. [105] Q. Ding, W. Xia, J. C. Liu, J. Y. Yang, D. F. Lee, J. Xia, G. Bartholomeusz, Y. Li, Y. Pan, Z. Li, R. C. Bargou, J. Qin, C. C. Lai, F. J. Tsai, C. H. Tsai, and M. C. Hung, 'Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin,' Mol Cell, vol. 19, pp. 159-70, Jul 22 2005. [106] J. Cui, X. Zhou, Y. Liu, Z. Tang, and M. Romeih, 'Wnt signaling in hepatocellular carcinoma: analysis of mutation and expression of beta-catenin, T-cell factor-4 and glycogen synthase kinase 3-beta genes,' J Gastroenterol Hepatol, vol. 18, pp. 280-7, Mar 2003. [107] C. Desbois-Mouthon, M. J. Blivet-Van Eggelpoel, E. Beurel, M. Boissan, R. Delelo, A. Cadoret, and J. Capeau, 'Dysregulation of glycogen synthase kinase-3beta signaling in hepatocellular carcinoma cells,' Hepatology, vol. 36, pp. 1528-36, Dec 2002. [108] K. C. Ban, H. Singh, R. Krishnan, and H. F. Seow, 'GSK-3beta phosphorylation and alteration of beta-catenin in hepatocellular carcinoma,' Cancer Lett, vol. 199, pp. 201-8, Sep 25 2003. [109] W. Xue, L. Zender, C. Miething, R. A. Dickins, E. Hernando, V. Krizhanovsky, C. Cordon-Cardo, and S. W. Lowe, 'Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas,' Nature, vol. 445, pp. 656-60, Feb 8 2007. [110] J. C. Sheu, G. T. Huang, P. H. Lee, J. C. Chung, H. C. Chou, M. Y. Lai, J. T. Wang, H. S. Lee, L. N. Shih, P. M. Yang, and et al., 'Mutation of p53 gene in hepatocellular carcinoma in Taiwan,' Cancer Res, vol. 52, pp. 6098-100, Nov 1 1992. [111] R. M. Lunn, Y. J. Zhang, L. Y. Wang, C. J. Chen, P. H. Lee, C. S. Lee, W. Y. Tsai, and R. M. Santella, 'p53 mutations, chronic hepatitis B virus infection, and aflatoxin exposure in hepatocellular carcinoma in Taiwan,' Cancer Res, vol. 57, pp. 3471-7, Aug 15 1997. [112] W. Beerheide, Y. J. Tan, E. Teng, A. E. Ting, A. Jedpiyawongse, and P. Srivatanakul, 'Downregulation of proapoptotic proteins Bax and Bcl-X(S) in p53 overexpressing hepatocellular carcinomas,' Biochem Biophys Res Commun, vol. 273, pp. 54-61, Jun 24 2000. [113] G. A. Turenne and B. D. Price, 'Glycogen synthase kinase3 beta phosphorylates serine 33 of p53 and activates p53's transcriptional activity,' BMC Cell Biol, vol. 2, p. 12, 2001. [114] P. Watcharasit, G. N. Bijur, L. Song, J. Zhu, X. Chen, and R. S. Jope, 'Glycogen synthase kinase-3beta (GSK3beta) binds to and promotes the actions of p53,' J Biol Chem, vol. 278, pp. 48872-9, Dec 5 2003. [115] G. N. Bijur and R. S. Jope, 'Proapoptotic stimuli induce nuclear accumulation of glycogen synthase kinase-3 beta,' J Biol Chem, vol. 276, pp. 37436-42, Oct 5 2001. [116] P. Watcharasit, G. N. Bijur, J. W. Zmijewski, L. Song, A. Zmijewska, X. Chen, G. V. Johnson, and R. S. Jope, 'Direct, activating interaction between glycogen synthase kinase-3beta and p53 after DNA damage,' Proc Natl Acad Sci U S A, vol. 99, pp. 7951-5, Jun 11 2002. [117] P. Sabbatini and F. McCormick, 'Phosphoinositide 3-OH kinase (PI3K) and PKB/Akt delay the onset of p53-mediated, transcriptionally dependent apoptosis,' J Biol Chem, vol. 274, pp. 24263-9, Aug 20 1999. [118] Y. Mitsuuchi, S. W. Johnson, M. Selvakumaran, S. J. Williams, T. C. Hamilton, and J. R. Testa, 'The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel,' Cancer Res, vol. 60, pp. 5390-4, Oct 1 2000. [119] A. Yamaguchi, M. Tamatani, H. Matsuzaki, K. Namikawa, H. Kiyama, M. P. Vitek, N. Mitsuda, and M. Tohyama, 'Akt activation protects hippocampal neurons from apoptosis by inhibiting transcriptional activity of p53,' J Biol Chem, vol. 276, pp. 5256-64, Feb 16 2001. [120] E. Sadot, B. Geiger, M. Oren, and A. Ben-Ze'ev, 'Down-regulation of beta-catenin by activated p53,' Mol Cell Biol, vol. 21, pp. 6768-81, Oct 2001. [121] R. P. de Groot, J. Auwerx, M. Bourouis, and P. Sassone-Corsi, 'Negative regulation of Jun/AP-1: conserved function of glycogen synthase kinase 3 and the Drosophila kinase shaggy,' Oncogene, vol. 8, pp. 841-7, Apr 1993. [122] P. Li, S. V. Nicosia, and W. Bai, 'Antagonism between PTEN/MMAC1/TEP-1 and androgen receptor in growth and apoptosis of prostatic cancer cells,' J Biol Chem, vol. 276, pp. 20444-50, Jun 8 2001. [123] Y. Wen, M. C. Hu, K. Makino, B. Spohn, G. Bartholomeusz, D. H. Yan, and M. C. Hung, 'HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway,' Cancer Res, vol. 60, pp. 6841-5, Dec 15 2000. [124] M. Sharma, W. W. Chuang, and Z. Sun, 'Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3beta inhibition and nuclear beta-catenin accumulation,' J Biol Chem, vol. 277, pp. 30935-41, Aug 23 2002. [125] A. Migliaccio, G. Castoria, M. Di Domenico, A. de Falco, A. Bilancio, M. Lombardi, M. V. Barone, D. Ametrano, M. S. Zannini, C. Abbondanza, and F. Auricchio, 'Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation,' EMBO J, vol. 19, pp. 5406-17, Oct 16 2000. [126] M. Sun, L. Yang, R. I. Feldman, X. M. Sun, K. N. Bhalla, R. Jove, S. V. Nicosia, and J. Q. Cheng, 'Activation of phosphatidylinositol 3-kinase/Akt pathway by androgen through interaction of p85alpha, androgen receptor, and Src,' J Biol Chem, vol. 278, pp. 42992-3000, Oct 31 2003. [127] D. A. Benitez, E. Pozo-Guisado, M. Clementi, E. Castellon, and P. M. Fernandez-Salguero, 'Non-genomic action of resveratrol on androgen and oestrogen receptors in prostate cancer: modulation of the phosphoinositide 3-kinase pathway,' Br J Cancer, vol. 96, pp. 1595-604, May 21 2007. [128] Y. I. Lee, S. Kang-Park, and S. I. Do, 'The hepatitis B virus-X protein activates a phosphatidylinositol 3-kinase-dependent survival signaling cascade,' J Biol Chem, vol. 276, pp. 16969-77, May 18 2001. [129] M. J. Bouchard and R. J. Schneider, 'The enigmatic X gene of hepatitis B virus,' J Virol, vol. 78, pp. 12725-34, Dec 2004. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/27233 | - |
| dc.description.abstract | 肝癌(Hepatocellular cacinoma)為台灣最常見的惡性腫瘤，在造成肝癌的危險因子中又以B型肝炎病毒(HBV)的感染最為重要，但HBV導致癌症發生過程可能的分子機轉到目前仍不清楚，而HBV引起的肝癌病例有個顯著的特徵是在性別上的偏好性，男性的罹病率相較於女性約高三~七倍左右。本實驗室先前研究中就已發現HBx具有正向調控男性荷爾蒙受體(androgen receptor)對帶有ARE(androgen-response element)基因的轉錄活性，而這可能是HBV相關肝癌好發於男性的可能機制。
在探討HBx促進男性荷爾蒙受體轉錄活化分子機制的研究中，我們著重在調控AR轉錄活性重要的兩步驟：AR N/C interaction及AR NTD活性。我們發現HBx可透過這兩個步驟來促進AR轉錄活性，分別藉由調控細胞中c-Src與GSK-3β的活性，我們首先證實了c-Src kinase活性在HBx促進AR NTD活性過程中扮演重要的角色，所以本研究接著想進一步探討HBx造成AR N/C interaction增加的機制為何。過去分別有文獻指出HBx可活化Erk kinase使GSK-3β活性受到抑制，且於prostate cancer cell中GSK-3β具有抑制AR N/C interaction的功能，因此我們假設於肝細胞中HBx或許可透過抑制GSK-3β的活性來造成AR N/C interaction的上升。這部分的研究成果大致簡述如下： (1)我們利用mammalian two-hybrid assay的方法證實了GSK-3β確實於肝細胞中在AR N/C interaction調控中扮演負調控的角色。 (2)在HepG2細胞株中，HBx的表現並不足以抑制GSK-3β，必須在AR與HBx的協同作用下，經AR ligand刺激下GSK-3β活性才受到抑制，GSK-3β活性遭抑制後AR N/C interaction就會增加，進而轉錄活化promoter帶有ARE的基因。 (3)針對GSK-3β調控的下游分子中最關鍵的β-catenin，我們進一步探討GSK-3β調控AR N/C interaction機制裡是否β-catenin有參與，實驗結果說明了GSK-3β並非藉由抑制β-catenin的活性來調控AR N/C interaction。 (4)最後，我們在分別證實了AR N/C interaction與AR NTD活性各自有GSK-3β與c-Src調控之後，想釐清這兩個步驟影響AR轉錄活性的程度，結果發現到HBx活化AR的轉錄活性主要就是藉由AR N/C interaction及AR NTD活性兩步驟加以調控，因此確立了GSK-3β與c-Src在HBx活化AR轉錄活性過程中的重要樞紐性質。 另一方面，被認為與HCC形成有關的抑癌基因p53，過去也有研究指出AR具有負調控AR N/C interaction的功能，所以我們假設p53在HBx促進AR轉錄活性增加的過程中，可能也是重要的負調控者。關於這部份的研究成果則簡述如下： (1) p53可透過抑制AR N/C interaction及AR NTD活性在HBx促進AR轉錄活性增加過程中扮演負調控者的角色。 (2) R249S突變的p53會失去抑制AR轉錄活性的功能。 (3)我們證實了GSK-3β的活性對於p53調控AR N/C interaction是重要的，但p53抑制AR轉錄活性不僅只倚賴GSK-3β的調控路徑。 在本研究中，我們證實了AR N/C interaction與AR NTD活性兩步驟是主要決定HBx 促進AR轉錄活性的關鍵，也針對AR N/C interaction的兩個負調控者GSK-3β及p53做了較深入的探討，希望藉由對HBx促進AR轉錄活化的負調控機制的了解，知曉如何阻礙細胞癌化的過程，而本研究結果可做為將來HBV相關男性肝癌治療上的參考。 | zh_TW |
| dc.description.provenance | Made available in DSpace on 2021-06-12T17:58:39Z (GMT). No. of bitstreams: 1 ntu-97-R94445132-1.pdf: 1481969 bytes, checksum: bca9e910ffad987855de85be32d418f5 (MD5) Previous issue date: 2008 | en |
| dc.description.tableofcontents | 口試委員會審定書…………………………………………………………………… i
中文摘要…………………………………………………………………………...… ii 英文摘要…………………………………………………………………………….. iv 序論…………………………………………………………………..…………….. 1 B型肝炎病毒與B型肝炎的發生 ………………………………………...… 1 B型肝炎與肝癌(HCC)形成之關係 ………………………………………… 1 B型肝炎病毒引起之肝癌有性別偏好性 …………………………………... 3 B型肝炎病毒X蛋白質(HBx)的功能與轉活化能力 ………………………. 3 HBx引發肝癌發生之動物模式研究 ……………………………………….. 5 男性荷爾蒙受體與肝癌形成的相關性 …………………………………….. 6 男性荷爾蒙受體之結構與功能 …………………………………………….. 7 男性荷爾蒙受體N端與C端間的交互作用及其調控 …………………….. 8 GSK-3β kinase特性及其調控方式 ………………………………………... 10 GSK-3β與肝癌發展過程的關係 ………………………………………….. 11 p53與肝癌發展過程的關係 …………………………………………….… 12 p53與GSK-3β之間可互相活化 …………………………………………. 13 研究目的 ………………………………………………………………………… 15 材料與方法 ……………………………………………………………………… 17 結果 …………………………………………………………………………….... 24 第一部份：探討GSK-3β在HBx促進AR轉錄活性過程中的角色 1. 探討HBx是否會經由影響AR NTD活化及AR N/C interaction兩步 驟促進AR的轉錄活性 ………..…………………………………..... 24 2. 探討GSK-3β是否可以調控HBx所促進的AR N/C interaction步驟... 25 3. 探討GSK-3β的活性在肝癌細胞株中是否會受HBx或是AR與HBx 協同活化的訊息傳導路徑所影響 ………………………...………… 26 4. 探討GSK-3β影響AR N/C interaction的可能機制 ………….……. 28 5. 探討AR轉錄活性的調控是否主要經由GSK-3β及c-Src分別調控 AR N/C interaction及AR NTD的活性 ………..……..……………… 30 6. 探討結合針對AR N/C interaction與AR NTD活性調節者的抑制劑， 對AR轉錄活性的影響 …………………..……………………....….. 32 第二部份：探討p53在HBx促進AR轉錄活性過程中的角色 1. 探討p53是否調控AR的轉錄活性，而R249S突變是否造成此調控 功能喪失 ……..………………………………………….………….... 34 2. 探討p53調控AR轉錄活性是否與影響AR N/C interaction有關 ….. 35 3. 探討p53是否調控AR NTD的活性 ………………………………… 37 4. 探討p53調控AR轉錄活性的可能機制 ……………………….…… 38 討論 …………………………………………………………………………........ 39 參考文獻 ………………………………………………………………..…..…… 47 圖附錄 ………………………………………………………………………….... 59 | |
| dc.language.iso | zh-TW | |
| dc.title | B型肝炎病毒X蛋白質所促進男性荷爾蒙轉錄活性機制中GSK-3β與p53負向調控角色之研究 | zh_TW |
| dc.title | Mechanism of HBx-enhanced AR transactivation：GSK-3β and p53 as two negative regulators | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 96-1 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 陳培哲,施修明 | |
| dc.subject.keyword | 男性荷爾蒙受體,B型肝炎病毒, | zh_TW |
| dc.subject.keyword | AR,HBx,GSK-3β,p53, | en |
| dc.relation.page | 76 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2008-01-29 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 微生物學研究所 | zh_TW |
| Appears in Collections: | 微生物學科所 | |
Files in This Item:
| File | Size | Format | |
|---|---|---|---|
| ntu-97-1.pdf Restricted Access | 1.45 MB | Adobe PDF |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.